Abstract: This invention is directed to compounds and compositions that have biological properties useful for modulating HGF/SF activity. In certain embodiments, said compounds and compositions may be used in the treatment and prophylaxis of cancer or other dysproliferative diseases.

Abstract: 2,4-Diaminoquinazolines of formulae I-IV and VI are useful for treating spinal muscular atrophy (SMA).

Abstract: A continuously variable transmission (CVT) includes an aluminum housing member having a bore formed therein. A rotatable pulley member is supported on a bearing within the bore. The bore includes a layer of thermal spray coating for improved wear resistance so that the bore supports the bearing without a steel sleeve therebetween.

Abstract: The present invention is directed to cyclic substituted fused pyrrolocarbazoles and isoindolones. The invention also is directed to methods for making and using the cyclic substituted fused pyrrolocarbazoles and isoindolones.

Abstract: The present invention is directed to novel heterocyclic substituted pyrazolones, including pharmaceutical compositions, diagnostic kits, assay standards or reagents containing the same, and methods of using the same as therapeutics. The invention is also directed to intermediates and processes for making these novel compounds.

Abstract: Methods for producing azole compounds useful as intermediates for antifungal compounds and compositions including reaction of epoxy alcohols with reactants having active hydrogen attached to nitrogen, oxygen or sulfur in the presence of redox coupling agents. In some embodiments, a procedure known as a Mitsunobu reaction is utilized for the transformations.

Abstract: Use of alkali metal carbonates to stabilize aqueous solutions of alkali metal aluminates.

Abstract: The present invention is directed to cyclic substituted fused pyrrolocarbazoles and isoindolones. The invention also is directed to methods for making and using the cyclic substituted fused pyrrolocarbazoles and isoindolones.

Abstract: Disclosed are compounds, compositions and methods for inhibiting interleukin-1&bgr; protease activity, the compounds having the formula (I).

Abstract: The present invention relates to the derivatives of specially substituted azole compounds which have improved antifungal activity as compared to known compounds such as fluconazole and itraconazole and the processes for the preparation thereof. This invention also relates to pharmaceutical compositions containing the compounds of the present invention and their use in treating and/or preventing fungal infections in mammals, preferably humans.

Abstract: The present invention is directed to novel heterocyclic substituted pyrazolones, including pharmaceutical compositions, diagnostic kits, assay standards or reagents containing the same, and methods of using the same as therapeutics. The invention is also directed to intermediates and processes for making these novel compounds.

Abstract: Disclosed are compounds, compositions, and methods for inhibiting interleukin-1&bgr; protease activity, wherein the compounds are &agr;-substituted methyl ketones having formula (I) as set forth herein. These compounds are inhibitors of IL-1&bgr; converting enzyme and as such are useful as therapeutic agents for certain infectious diseases.

Abstract: A leg assembly for a vehicle passenger seat comprises a front leg frame and a rear leg comprising a first link pivotally connected at a first end to the rear foot, a second link pivotally connected at a first end to an intermediate point on the leg frame and a load-limiting strut pivotally connected at a first end to the front foot and pivotally connected at a second end to both the second end of the first link and the second end of the second link. The load-limiting strut is arranged to resist movement of the first and second links into alignment with each other, but to yield when subject to a load exceeding a predetermined value, thereby allowing the seat to pivot forwardly about its front foot.

Abstract: The present invention is directed to novel heterocyclic substituted pyrazolones, including pharmaceutical compositions, diagnostic kits, assay standards or reagents containing the same, and methods of using the same as therapeutics. The invention is also directed to intermediates and processes for making these novel compounds.

Abstract: The invention relates to MR contrast media containing composite nanoparticles, preferably comprising a superparamagnetic iron oxide core provided with a coating comprising an oxidatively cleaved starch coating optionally together with a functionalized polyalkyleneoxide which serves to prolong blood residence.

Abstract: A leg assembly for a vehicle passenger seat comprises a front leg frame and a rear leg comprising a first link pivotally connected at a first end to the rear foot, a second link pivotally connected at a first end to an intermediate point on the leg frame and a load-limiting strut pivotally connected at a first end to the front foot and pivotally connected at a second end to both the second end of the first link and the second end of the second link. The load-limiting strut is arranged to resist movement of the first and second links into alignment with each other, but to yield when subject to a load exceeding a predetermined value, thereby allowing the seat to pivot forwardly about its front foot.

Abstract: The present invention is directed to novel fused aryl and heteroaryl bridged indenopyrrolocarbazoles which are useful, inter alia, as therapeutic agents. The invention is also directed to methods for making and using the bridged indenopyrrolocarbazoles.

Abstract: The invention provides a complexant compound of formula I R3S(CR12)nN(R2)i(CR12)nX(CR12)nN(R2)i(CR12)nSR3  (I) (wherein each n, which may be the same or different, is an integer 2, 3 or 4 (preferably 2); each i, which may be the same or different, represents 0 or 1; each R3, which may be the same or different, is H or a thiol protecting group, preferably a protecting group; X is O, S, N, NR4 or a substituted phosphorus (eg.

Abstract: The present invention is directed to novel fused aryl and heteroaryl bridged indenopyrrolocarbazoles which are useful, inter alia, as therapeutic agents. The invention is also directed to methods for making and using the bridged indenopyrrolocarbazoles.

Abstract: The invention provides a complexant compound of formula IR.sup.3 S (CR.sup.1.sub.2).sub.n N(R.sup.2).sub.i (CR.sup.1.sub.2).sub.n X(CR.sup.1.sub.2).sub.n N(R.sup.2).sub.i (CR.sup.1.sub.2).sub.n SR.sup.3(I )(wherein each n, which may be the same or different, is an integer 2, 3 or 4 (preferably 2); each i, which may be the same or different, represents 0 or 1; each R.sup.3, which may be the same or different, is H or a thiol protecting group, preferably a protecting group; X is O, S, N, NR.sup.4 or a substituted phosphorus (eg. oxo substituted phosphorus), preferably S or N; each R.sup.4, which may be the same or different, is hydrogen or an optionally substituted organic group; each R.sup.1, which may be the same or different, is hydrogen or an optionally substituted organic group, or a moiety CR.sup.1.sub.2 may represents a carbonyl group or two, three or four R.sup.